Zai Lab Limited  announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA):

• VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive;
• NUZYRA® (omadacycline) is renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI); and
• ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.

“The successful renewal of VYVGART®, NUZYRA® and ZEJULA® reflects the continued recognition of their strong clinical value. We are pleased to now have six products included on the NRDL, which reduces the disease burden on patients by enabling broad patient access to high-quality, novel medicines. We thank the NHSA for their ongoing support for the innovation in China and its efforts to include more new and effective drugs in the NRDL. Zai Lab will continue to enhance the accessibility and affordability of our medicines so that patients in need can benefit from innovative therapies as early as possible,” said Andrew Zhu, Chief Commercial Officer of Zai Lab in mainland China, Hong Kong, Macau, and Taiwan (Greater China).